NASDAQ:ABSI Absci (ABSI) Stock Price, News & Analysis → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Free ABSI Stock Alerts $4.53 -0.18 (-3.82%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$4.48▼$4.8950-Day Range$4.51▼$6.5952-Week Range$1.11▼$6.72Volume854,438 shsAverage Volume1.52 million shsMarket Capitalization$510.94 millionP/E RatioN/ADividend YieldN/APrice Target$9.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Absci alerts: Email Address Absci MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside104.2% Upside$9.25 Price TargetShort InterestBearish13.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 2 Articles This WeekInsider TradingAcquiring Shares$999,999 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.76) to ($0.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.38 out of 5 starsMedical Sector481st out of 909 stocksCommercial Physical Research Industry9th out of 12 stocks 3.5 Analyst's Opinion Consensus RatingAbsci has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAbsci has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.01% of the float of Absci has been sold short.Short Interest Ratio / Days to CoverAbsci has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Absci has recently decreased by 1.87%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAbsci does not currently pay a dividend.Dividend GrowthAbsci does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ABSI. Previous Next 1.8 News and Social Media Coverage News SentimentAbsci has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Absci this week, compared to 1 article on an average week.Search InterestOnly 15 people have searched for ABSI on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 18 people have added Absci to their MarketBeat watchlist in the last 30 days. This is a decrease of -18% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Absci insiders have bought more of their company's stock than they have sold. Specifically, they have bought $999,999.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders11.58% of the stock of Absci is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.05% of the stock of Absci is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Absci are expected to grow in the coming year, from ($0.76) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Absci is -3.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Absci is -3.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbsci has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About Absci Stock (NASDAQ:ABSI)Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.Read More ABSI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABSI Stock News HeadlinesApril 20, 2024 | finance.yahoo.comAbsci Corporation (ABSI)April 16, 2024 | finance.yahoo.comAbsci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024April 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...March 28, 2024 | finance.yahoo.comAbsci to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 23, 2024 | finance.yahoo.comAbsci Corp (ABSI) Earnings: Misses Revenue Estimates and Reports Increased Net LossMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for AbSci: Promising Pipeline and Strategic Partnerships Signal GrowthMarch 21, 2024 | benzinga.comAbsci: Q4 Earnings InsightsMarch 21, 2024 | investorplace.comABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q4 2023April 24, 2024 | Behind the Markets (Ad)Pentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...March 21, 2024 | globenewswire.comAbsci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating ResultsMarch 13, 2024 | finance.yahoo.comABSI Apr 2024 6.000 callMarch 7, 2024 | investing.comAbsci shares get buy rating, $9 target on AI biotech potentialMarch 1, 2024 | finance.yahoo.comAbsci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional SharesMarch 1, 2024 | globenewswire.comAbsci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters' Option to Purchase Additional SharesFebruary 28, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on AbSci (ABSI)February 28, 2024 | msn.comWhy Absci (ABSI) Shares Are FallingFebruary 28, 2024 | msn.comAbsci prices $75M equity offering at $4.50 per shareFebruary 27, 2024 | globenewswire.comAbsci Announces Pricing of Public Offering of Common StockFebruary 27, 2024 | globenewswire.comAbsci Announces Proposed Public Offering of Common StockFebruary 24, 2024 | ca.finance.yahoo.comCNC Mar 2024 86.000 callFebruary 21, 2024 | finance.yahoo.comIs Centene (CNC) Stock Outpacing Its Medical Peers This Year?February 21, 2024 | finance.yahoo.comAbsci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AIFebruary 21, 2024 | globenewswire.comAbsci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AIFebruary 16, 2024 | finance.yahoo.comABSI Mar 2024 7.500 callFebruary 16, 2024 | finance.yahoo.comABSI Feb 2024 7.500 putFebruary 5, 2024 | finance.yahoo.comIs Absci Corporation (ABSI) Outperforming Other Medical Stocks This Year?January 21, 2024 | finance.yahoo.comBoth retail investors who control a good portion of Absci Corporation (NASDAQ:ABSI) along with institutions must be dismayed after last week's 15% decreaseSee More Headlines Receive ABSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Absci and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/24/2024Next Earnings (Confirmed)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:ABSI CUSIPN/A CIK1672688 Webwww.absci.com Phone360-949-1041FaxN/AEmployees155Year FoundedN/APrice Target and Rating Average Stock Price Target$9.25 High Stock Price Target$13.00 Low Stock Price Target$7.00 Potential Upside/Downside+98.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,570,000.00 Net Margins-1,933.65% Pretax Margin-1,931.90% Return on Equity-44.52% Return on Assets-37.35% Debt Debt-to-Equity Ratio0.03 Current Ratio4.08 Quick Ratio4.08 Sales & Book Value Annual Sales$5.72 million Price / Sales91.69 Cash FlowN/A Price / Cash FlowN/A Book Value$1.90 per share Price / Book2.45Miscellaneous Outstanding Shares112,790,000Free Float99,724,000Market Cap$524.47 million OptionableOptionable Beta2.36 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Sean McClain (Age 33)Founder, CEO, President & Director Comp: $936.2kDr. Zachariah Jonasson Ph.D. (Age 50)Chief Business Officer & CFO Comp: $98.3kDr. Andreas Busch Ph.D. (Age 61)Chief Innovation Officer & Member of Scientific Advisory Board Comp: $1.56MMr. Todd Bedrick CPASenior VP & Chief Accounting OfficerMr. Alexander Khan CPAVP of Finance & Head of Investor RelationsMs. Karin WierinckChief People OfficerMelissa Patterson Ph.D.Chief of StaffJens Plassmeier Ph.D.Senior VP of Biologics Discovery TechnologyMr. Wen ShaChief of StaffDr. Christine Lemke D.V.M.M.B.A., Ph.D., Senior Vice President of Portfolio & Growth StrategyMore ExecutivesKey CompetitorsOmniAbNASDAQ:OABIORIC PharmaceuticalsNASDAQ:ORICMaxCyteNASDAQ:MXCTIradimedNASDAQ:IRMDTalkspaceNASDAQ:TALKView All CompetitorsInsiders & InstitutionsSumitomo Mitsui Trust Holdings Inc.Bought 420,812 shares on 4/19/2024Ownership: 0.373%Cannon Global Investment Management LLCBought 18,272 shares on 4/17/2024Ownership: 0.016%Salem Investment Counselors Inc.Bought 21,442 shares on 4/11/2024Ownership: 0.019%Redmile Group, LlcBought 222,222 shares on 3/1/2024Total: $999,999.00 ($4.50/share)Platinum Investment Management Ltd.Sold 469,072 shares on 2/14/2024Ownership: 0.901%View All Insider TransactionsView All Institutional Transactions ABSI Stock Analysis - Frequently Asked Questions Should I buy or sell Absci stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Absci in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABSI shares. View ABSI analyst ratings or view top-rated stocks. What is Absci's stock price target for 2024? 4 Wall Street research analysts have issued twelve-month price objectives for Absci's shares. Their ABSI share price targets range from $7.00 to $13.00. On average, they expect the company's stock price to reach $9.25 in the next year. This suggests a possible upside of 104.2% from the stock's current price. View analysts price targets for ABSI or view top-rated stocks among Wall Street analysts. How have ABSI shares performed in 2024? Absci's stock was trading at $4.20 at the start of the year. Since then, ABSI stock has increased by 7.9% and is now trading at $4.53. View the best growth stocks for 2024 here. When is Absci's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ABSI earnings forecast. How can I listen to Absci's earnings call? Absci will be holding an earnings conference call on Tuesday, May 14th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Absci's earnings last quarter? Absci Co. (NASDAQ:ABSI) announced its quarterly earnings results on Thursday, March, 21st. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.02. The company had revenue of $0.34 million for the quarter, compared to the consensus estimate of $1.75 million. Absci had a negative trailing twelve-month return on equity of 44.52% and a negative net margin of 1,933.65%. What ETF holds Absci's stock? ARK Genomic Revolution ETF holds 3,164,891 shares of ABSI stock, representing 1.31% of its portfolio. When did Absci IPO? Absci (ABSI) raised $200 million in an IPO on Thursday, July 22nd 2021. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. Who are Absci's major shareholders? Absci's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.37%), Salem Investment Counselors Inc. (0.02%) and Cannon Global Investment Management LLC (0.02%). Insiders that own company stock include Karen K Mcginnis, Redmile Group, Llc, Sarah Korman, Sean Mcclain and Todd Bedrick. View institutional ownership trends. How do I buy shares of Absci? Shares of ABSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABSI) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceFed launches fourth dollar overhaulStansberry ResearchNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Absci Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
